Stopping diabetes in its tracks: Autologous non-myeloablative stem cell transplantation

Georgia Fousteri, Alberto Hayek, Matthias von Herrath

Research output: Contribution to journalArticlepeer-review


A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.

Original languageEnglish
Pages (from-to)845-851
Number of pages7
JournalRegenerative Medicine
Issue number5
Publication statusPublished - Sep 2007


  • Anti-CD3
  • Anti-thymocyte globulin
  • Cyclophosphamide
  • Diabetes
  • Human trial
  • Non-myeloablative stem cell transplantation
  • Tregs

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology


Dive into the research topics of 'Stopping diabetes in its tracks: Autologous non-myeloablative stem cell transplantation'. Together they form a unique fingerprint.

Cite this